[Atypical antipsychotics].
Naber
D
D
D000208:Acute Disease; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines; D003024:Clozapine / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003987:Dibenzothiazepines / Q000627:therapeutic use; D003988:Dibenzothiepins / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control; D005858:Germany; D006801:Humans; D018377:Neurotransmitter Agents / Q000191:economics / Q000627:therapeutic use*; D000077152:Olanzapine; D010349:Patient Compliance; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics; D013469:Sulpiride / Q000031:analogs & derivatives / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D003988:Dibenzothiepins; D018377:Neurotransmitter Agents; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; D013469:Sulpiride; D000077582:Amisulpride; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine; C022172:zotepine